Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
By Qing Zhou, Meghan E. Munger, Rachelle G. Veenstra, B. Weigel, M. Hirashima, D. Munn, W. Murphy, M. Azuma, A. Anderson, V. Kuchroo and 1 more. Blood, 2011
659 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/75044c96d1cdc1fd168b05c8b893cc4c4fac2fec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review (2018, background): “CD8+ T cells expressing both PD‐1 and Tim‐3 tend more into exhaustion state than the cells expressing either one alone (Zhou et al., 2011).”
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012, positive): “Indeed, in an animal model of acute myelogenous leukemia (AML), blockade of PD-1 or Tim-3 alone was insufficient to rescue mice from cancer progression, while blockade of both pathways resulted in additive disease protection [38].”
- T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment (2013, background): “In the course of defining exhausted PD1 T cells, T cell immunoglobulin and mucin-domaincontaining molecule-3 (Tim-3) [39 ,41], lymphocyteactivation gene (LAG)-3 [38], and the B and T-cell lymphocyte attenuator (BTLA, CD272) [42,43] were found to be co-expressed with PD-1, and the co-expression has b”